70/100BJohnson & Johnson stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Johnson & Johnson is 285.31, 0.0% below the current price of 285.45. Their targets range from 260.00 to 320.00.
Of the 19 firms that rated Johnson & Johnson in the past 12 months, 12 rate it buy or strong buy, 7 hold and 0 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 260.00 to 320.00, with an average of 285.31.
| Buy | 12 | |
| Hold | 7 | |
| Sell | 0 |
12-month price target
| Highest target | 320.00 |
| Average target | 285.31 |
| Lowest target | 260.00 |
| Current price | 285.45 |
Johnson & Johnson price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Johnson & Johnson price target and rating?
How analysts rate Johnson & Johnson, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12 of 19 firms rate it buy now, against 7 of 16 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Johnson & Johnson analyst upgrades, downgrades and price targets
The latest rating change came on 13 May 2026, when Leerink Partners upgraded Johnson & Johnson from Market Perform to Outperform. Its price target is 265.00. The most recent new target came from Evercore ISI on 20 October 2026: 300.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 20 Oct 2026 | Evercore ISI | — | 300.00 | — | 258.74 |
| 16 Oct 2026 | Wells Fargo Larry Biegelsen | Reiterated · Overweight | 275.00 → 287.00 | +4.4% | 253.28 |
| 15 Oct 2026 | Bernstein Lee Hambright | — | 208.00 → 270.00 | +29.8% | 259.85 |
| 14 Oct 2026 | RBC Capital | Reiterated · Outperform | 290.00 → 280.00 | -3.4% | 251.68 |
| 14 Oct 2026 | Leerink Partners | Reiterated · Outperform | 265.00 → 272.00 | +2.6% | 251.75 |
| 14 Oct 2026 | Wells Fargo Larry Biegelsen | Reiterated · Overweight | 282.00 → 275.00 | -2.5% | 248.61 |
| 14 Oct 2026 | UBS | — | 320.00 → 270.00 | -15.6% | 248.61 |
| 6 Oct 2026 | RBC Capital Shagun Singh | Reiterated · Outperform | 287.00 → 290.00 | +1.0% | 252.93 |
| 29 Sept 2026 | New Street | — | 278.00 | — | 271.95 |
| 10 Sept 2026 | HSBC | Reiterated · Buy | 290.00 → 320.00 | +10.3% | 267.08 |
| 2 Sept 2026 | UBS | Reiterated · Buy | 214.00 → 320.00 | +49.5% | 271.19 |
| 6 Aug 2026 | Guggenheim | Reiterated · Buy | 270.00 → 287.00 | +6.3% | 257.59 |
| 3 Aug 2026 | Raymond James | — | 265.00 → 280.00 | +5.7% | 254.45 |
| 3 Aug 2026 | Wells Fargo | Reiterated · Overweight | 272.00 → 282.00 | +3.7% | 256.35 |
| 29 Jul 2026 | Argus Research David Toung | — | 210.00 → 300.00 | +42.9% | 266.13 |
| 16 Jul 2026 | Johnson Rice Ilya Zubkov | — | 261.00 → 280.00 | +7.3% | 249.76 |
| 16 Jul 2026 | Scotiabank | — | 265.00 → 305.00 | +15.1% | 248.95 |
| 16 Jul 2026 | Raymond James | Reiterated · Outperform | 209.00 → 265.00 | +26.8% | 250.50 |
| 16 Jul 2026 | Johnson Rice | — | 270.00 → 261.00 | -3.3% | 250.49 |
| 16 Jul 2026 | Goldman Sachs | — | 250.00 → 282.00 | +12.8% | 247.02 |
| 16 Jul 2026 | Morgan Stanley Terence Flynn | Reiterated · Overweight | 284.00 → 294.00 | +3.5% | 247.02 |
| 16 Jul 2026 | Wells Fargo | Reiterated · Overweight | 240.00 → 272.00 | +13.3% | 247.02 |
| 15 Jul 2026 | Stifel Nicolaus Rick Wise | — | 250.00 → 260.00 | +4.0% | 247.02 |
| 13 Jul 2026 | RBC Capital | Reiterated · Outperform | 265.00 → 287.00 | +8.3% | 257.61 |
| 8 Jul 2026 | Morgan Stanley Terence Flynn | Reiterated · Overweight | 283.00 → 284.00 | +0.4% | 267.24 |
| 6 Jul 2026 | HSBC | — | 240.00 → 290.00 | +20.8% | 258.66 |
| 26 Jun 2026 | Guggenheim Vamil Divan | Reiterated · Buy | 266.00 → 270.00 | +1.5% | 253.56 |
| 26 Jun 2026 | Johnson Rice | — | 190.00 → 270.00 | +42.1% | 253.29 |
| 13 May 2026 | Leerink Partners David Risinger | Upgraded · Market Perform → Outperform | 265.00 | — | 224.26 |
| 20 Apr 2026 | Guggenheim | — | 240.00 → 266.00 | +10.8% | 232.71 |
| 15 Apr 2026 | Morgan Stanley | — | 267.00 → 283.00 | +6.0% | 239.66 |
| 15 Apr 2026 | RBC Capital | — | 255.00 → 265.00 | +3.9% | 240.10 |
| 15 Apr 2026 | Stifel Nicolaus Rick Wise | Reiterated · Hold | 220.00 → 250.00 | +13.6% | 240.10 |
| 15 Apr 2026 | Barclays Matt Miksic | Reiterated · Equal Weight | 217.00 → 255.00 | +17.5% | 240.10 |
| 10 Apr 2026 | Morgan Stanley | Reiterated · Overweight | 253.00 → 267.00 | +5.5% | 239.50 |
| 18 Mar 2026 | Morgan Stanley | — | 262.00 → 253.00 | -3.4% | 237.19 |
| 3 Feb 2026 | RBC Capital | Reiterated · Outperform | 240.00 → 255.00 | +6.3% | 233.35 |
| 28 Jan 2026 | Morgan Stanley Terrance Flynn | Upgraded · Equal Weight → Overweight | 200.00 → 262.00 | +31.0% | 224.44 |
| 27 Jan 2026 | Loop Capital Markets Ilya Zubkov | — | 190.00 → 220.00 | +15.8% | 225.16 |
| 23 Jan 2026 | Guggenheim Vamil Divan | Reiterated · Buy | 227.00 → 240.00 | +5.7% | 218.49 |
| 22 Jan 2026 | Scotiabank | Reiterated · Sector Outperform | 265.00 | — | 220.18 |
| 22 Jan 2026 | Morgan Stanley Terence Flynn | Reiterated · Equal Weight | 197.00 → 200.00 | +1.5% | 220.37 |
| 22 Jan 2026 | Stifel Nicolaus Rick Wise | Reiterated · Hold | 190.00 → 220.00 | +15.8% | 218.01 |
| 22 Jan 2026 | Goldman Sachs Asad Haider | — | 240.00 → 250.00 | +4.2% | 218.01 |
| 22 Jan 2026 | Wells Fargo | Reiterated · Overweight | 212.00 → 240.00 | +13.2% | 218.01 |
| 9 Jan 2026 | Bernstein Lee Hambright | Reiterated · Market Perform | 193.00 → 208.00 | +7.8% | 205.75 |
| 30 Dec 2025 | Barclays Matt Miksic | Reiterated · Equal Weight | 197.00 → 217.00 | +10.2% | 207.56 |
| 18 Dec 2025 | Goldman Sachs Asad Haider | — | 240.00 | — | 210.33 |
| 17 Dec 2025 | RBC Capital | — | 230.00 → 240.00 | +4.3% | 209.08 |
| 12 Dec 2025 | Morgan Stanley | Reiterated · Equal Weight | 190.00 → 197.00 | +3.7% | 210.60 |
Johnson & Johnson EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Johnson & Johnson's EPS to grow 8.2% a year until 2028, slower than over the last 5 years (14.9% a year) and the last 3 years (17.9%).
Analysts expect Johnson & Johnson's revenue to grow 7.4% a year until 2028. Over the last 5 years it grew 2.7% a year, and over the last 3 years 5.6%.
Revenue
EPS
Does Johnson & Johnson beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 3.1% off the result, either way, and their revenue estimate 1.3%, over the last 12 quarters.
- EPS beats
- 111 / 136
- Revenue beats
- 82 / 108
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +3.1%
- Since
- February 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 13 Oct 2026 | 2.52 | 2.59 | +2.8% | 25.38B | 25.40B | +0.1% |
| Q2 FY2026 | 15 Jul 2026 | 2.85 | 2.90 | +1.8% | 25.06B | 25.31B | +1.0% |
| Q1 FY2026 | 14 Apr 2026 | 2.68 | 2.70 | +0.7% | 23.61B | 24.06B | +1.9% |
| Q4 FY2025 | 21 Jan 2026 | 2.46 | 2.46 | 0.0% | 24.15B | 24.56B | +1.7% |
| Q3 FY2025 | 14 Oct 2025 | 2.76 | 2.80 | +1.4% | 23.76B | 23.99B | +1.0% |
| Q2 FY2025 | 16 Jul 2025 | 2.68 | 2.77 | +3.4% | 22.85B | 23.74B | +3.9% |
| Q1 FY2025 | 15 Apr 2025 | 2.58 | 2.77 | +7.4% | 21.56B | 21.89B | +1.6% |
| Q4 FY2024 | 22 Jan 2025 | 1.99 | 2.04 | +2.5% | 22.43B | 22.52B | +0.4% |
| Q3 FY2024 | 15 Oct 2024 | 2.21 | 2.42 | +9.5% | 22.17B | 22.47B | +1.3% |
| Q2 FY2024 | 17 Jul 2024 | 2.71 | 2.82 | +4.1% | 22.33B | 22.45B | +0.5% |
| Q1 FY2024 | 16 Apr 2024 | 2.64 | 2.71 | +2.7% | 21.40B | 21.38B | -0.1% |
| Q4 FY2023 | 23 Jan 2024 | 2.27 | 2.29 | +0.9% | 20.99B | 21.40B | +1.9% |
Johnson & Johnson stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Johnson & Johnson's earnings keep growing at the 8.9% a year analysts expect to FY2028, it would earn about 16.56 a share in FY2030. At the P/E it has traded at over the last five years (11.3 to 43.3) that is 186.95 to 716.48 a share, or 401.27 at its average P/E of 24.2. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 11.11 | 125.50 | 269.38 | 480.99 |
| FY2027 | 11.59 | 130.86 | 280.87 | 501.51 |
| FY2028 | 13.96 | 157.59 | 338.24 | 603.94 |
| FY2029 (extrapolated) | 15.20 | 171.64 | 368.41 | 657.81 |
| FY2030 (extrapolated) | 16.56 | 186.95 | 401.27 | 716.48 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 8.9% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (11.3, 24.2, 43.3).
Is Johnson & Johnson stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Johnson & Johnson's P/E of 43.3 is near the top of its 5-year range (9.4 to 43.3, median 23.3). It is within 5% of its 5-year high. Analysts do not expect faster growth than in recent years, so it is expensive compared with its own history. Buyers pay more for each point of growth than usual: a PEG of 5.3 on expected growth against 1.6 on its median P/E and past five years' growth. Fair value is not a reliable guide for Johnson & Johnson: its earnings swing (EPS fell 57.8% in FY2024), so its usual P/E would mislead. Its forward P/E, on the consensus for FY2026, is 25.7.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 43.28
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 23.31
- Five-year P/E range
- 9.4 – 43.3
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 25.68
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 4.85
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- -0.0%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.850 | 71.4258Price 35.85193 | +99.2% | |
| 29.050 | 56.2634Price 29.0596 | +93.7% | |
| 241.000 | 464.49205Price 241.00627 | +92.7% | |
| 123.590 | 237.24178Price 123.59297 | +92.0% | |
| 161.400 | 305.52159Price 161.40396 | +89.3% | |
| 157.460 | 297.58169Price 157.46471 | +89.0% | |
| 217.560 | 405.38304Price 217.56507 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.